SBIR/STTR Research Award
Novel Beetle Luciferases for Biomedical Development
Award amount
$737,548Program and phase
SBIR · Phase IIAward year
1995Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- PROMEGA CORP.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Though radioactivity is widely used in bioassays due to its high sensitivity and convenience, safety and environmental concerns have accelerated efforts to eliminate its use. Recent procedures using luminescence have often surpassed conventional isotopic methods; among these the luminescence of firefly luciferase is the most efficient. Relevant biomedical applications include reporter gene technology, viral and cell tracer methods, non-isotopic immunoassays and other probe technologies, and clinical biomass/viability assays. Through fundamental research on the enzymatic mechanism of beetle luciferases, we have developed new chemistry which provides greater luminescence intensity with simpler reaction kinetics. To better understand the commercial potential of beetle luciferases and to develop specific enzymes suited for applications, we are currently examining the structure and function of several adult-form isozymes. This project is for extending our investigations to include a new class of isozymes derived from embryonic and juvenile developmental forms of elaterid beetles. These isozymes are spectrally unique, and taxonomic data reveals that they are evolutionarily divergent. Yet, due to inaccessibility, these enzymes have never been investigated biochemically. In Phase l, genes encoding these novel isozymes will be isolated to allow for enzymological and physical studies of the recombinant enzymes planned for Phase II.
Technology keywords
Not reported